


I. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-55 (canceled)

~~56.~~ (Currently Amended) ~~The compound of Claim 53, which is a~~ A compound of formula XX:



wherein

Q' is methylene;

each X is independently -O- or -NH-;



each R<sup>1</sup> is independently methyl or chloro;


each R<sup>2</sup> is independently 1,2-ethylene, 1,3-propylene, (2R)-2-(methyl)ethane-1,2-diyl, (2S)-2-(methyl)ethane-1,2-diyl, 1-(methyl)butane-1,4-diyl, 1-(methyl)ethane-1,2-diyl, or 2,2-(dimethyl)propane-1,3-diyl;

each Y is -NH<sub>2</sub>;

or a pharmaceutically-acceptable salt thereof.

~~57.~~ (Currently Amended) The compound of Claim ~~56~~, which is any one of compounds 27, and 28, 29, 30, 31, 36, and 37:





or a pharmaceutically acceptable salt thereof.

Claims 58-61 (canceled)

3  
62. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound as described in Claim 40 Claim 56 and a pharmaceutically acceptable carrier.

4  
63. (Currently Amended) A method of treating a disease or condition associated with sodium channel activity in a mammal, comprising administering to the mammal, a

Page 3 of 12

Serial No. 10/824,738  
Attorney Docket No.: P-097-US2  
Amendment and Response

therapeutically effective amount of a pharmaceutical composition comprising a compound as described in ~~Claim 40~~ Claim 5<sup>1</sup> and a pharmaceutically acceptable carrier.

<sup>4</sup>  
~~64~~. (Previously Presented) The method of Claim ~~63~~ <sup>4</sup> wherein the disease or condition is neuropathic pain.